GlassScriptPhysician profile
Kafele T Hodari
NPI 1952527319
$84,196.79
in general payments reported to CMS, 2019-2025
30 companies · $2,052 in 2025
The $2,052 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $5,074 · 2021: $28K · 2022: $13K · 2023: $12K · 2024: $2,373 · 2025: $2,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,399 · Food and Beverage: $4,394 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,768 · Travel and Lodging: $1,716 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,399.17 |
| Food and Beverage | $4,393.89 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,768.45 |
| Travel and Lodging | $1,715.71 |
| Education | $103.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $54,123.78 | 2019-2023 | |
| Abbvie INC. | $14,159.71 | 2019-2025 | |
| Pfizer INC. | $10,339.85 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,210.60 | 2019-2025 | |
| Lilly USA, LLC | $580.93 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Leo Pharma INC. | $502.28 | 2020-2025 | Adbry, Anzupgo |
| Ucb, INC. | $493.02 | 2019-2025 | Cimzia, Bimzelx |
| Genzyme Corporation | $393.28 | 2019-2025 | |
| Janssen Biotech, INC. | $366.84 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $300.63 | 2020-2024 | Dupixent, Libtayo |
| Merz North America, INC. | $239.40 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $231.31 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $221.19 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $199.79 | 2020-2025 | Winlevi, Absorica Ld, Ilumya |
| Biofrontera INC. | $116.10 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $87.48 | 2022-2023 | Vtama |
| Dermira, INC. | $83.95 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $79.00 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $78.99 | 2021-2024 | Jublia |
| Revance Therapeutics, INC. | $66.98 | 2025 | Daxxify |
| Amgen INC. | $64.81 | 2019-2024 | Otezla |
| Merck Sharp & Dohme LLC | $50.12 | 2019 | |
| Prugen, INC. Pharmaceuticals | $35.93 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.23 | 2023-2024 | Cyltezo |
| Strata Skin Sciences, INC. | $28.26 | 2019-2023 | Xtrac |
| Almirall LLC | $27.65 | 2019 | |
| Promius Pharma LLC | $25.39 | 2019 | |
| Mimedx Group, INC. | $20.06 | 2025 | |
| Botanix Sb INC | $19.99 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $15.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kafele Hodari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.